NAD+ depletion links metabolic stress to drive innate immune priming and selectively control PANoptosis
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag203 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Roman Sarkar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, United States. Hauptthemen laut MEDLINE: NAD, Macrophages, Regulated Cell Death. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
The innate immune system can detect infection, tissue damage, and other homeostatic disruptions to initiate an immune response, drive inflammation, and promote programmed cell death. While these responses can be beneficial in host defense, aberrant activation of inflammatory, lytic cell death pathways can be pathogenic. Emerging evidence suggests that cellular metabolic disruption can promote inflammatory cell death, but the mechanistic connections between these processes are not well understood, limiting our ability to identify regulatory nodes that can be therapeutically targeted. Here, we found that intracellular levels of the metabolic cofactor nicotinamide adenine dinucleotide (NAD+) were depleted in response to cell death triggers that drive pyroptosis, necroptosis, PANoptosis, and ferroptosis. However, restoring NAD+ inhibited PANoptosis but not the other forms of cell death. Mechanistically, NAD+ restoration reduced the expression of PANoptotic sensors or regulators, including the transcription factor IRF1, a critical factor for innate immune sensor priming in PANoptosis. Our findings thereby suggest that NAD+ depletion is an early cell death signaling event and that restoring NAD+ levels specifically blocks PANoptosis by suppressing priming. Hence, targeting NAD+ metabolism represents a potential therapeutic strategy for infectious and inflammatory diseases associated with dysregulated PANoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, United States.
ORCID-Profile: Thirumala-Devi Kanneganti
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIH HHS
- American Lebanese Syrian Associated Charities
- National Institutes of Health
Zitieren
APA
Sarkar, R., Pandian, N., Sundaram, B., Sharma, B. R., Gorsuch, P. A., Tweedell, R. E., & Kanneganti, T. D. (2026). NAD+ depletion links metabolic stress to drive innate immune priming and selectively control PANoptosis. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag203
Vancouver
Sarkar R, Pandian N, Sundaram B, Sharma BR, Gorsuch PA, Tweedell RE, et al. NAD+ depletion links metabolic stress to drive innate immune priming and selectively control PANoptosis. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag203
BibTeX
@article{Sarkar2026,
author = {Sarkar, Roman and Pandian, Nagakannan and Sundaram, Balamurugan and Sharma, Bhesh Raj and Gorsuch, Peter A and Tweedell, Rebecca E and Kanneganti, Thirumala-Devi},
title = {NAD+ depletion links metabolic stress to drive innate immune priming and selectively control PANoptosis},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag203}
}
EUVIMED